BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30730240)

  • 1. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
    Lentz R; Feinglass J; Ma S; Akhter N
    Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
    Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
    Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
    Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
    PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).
    Shanafelt TD; Parikh SA; Noseworthy PA; Goede V; Chaffee KG; Bahlo J; Call TG; Schwager SM; Ding W; Eichhorst B; Fischer K; Leis JF; Chanan-Khan AA; Hallek M; Slager SL; Kay NE
    Leuk Lymphoma; 2017 Jul; 58(7):1630-1639. PubMed ID: 27885886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
    Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
    Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
    Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
    Leong DP; Caron F; Hillis C; Duan A; Healey JS; Fraser G; Siegal D
    Blood; 2016 Jul; 128(1):138-40. PubMed ID: 27247135
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat CLL patients with ibrutinib.
    Brown JR
    Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
    Fradley MG; Gliksman M; Emole J; Viganego F; Rhea I; Welter-Frost A; Armanious M; Lee DH; Walko C; Shah B; Chavez JC; McLeod H; Pinilla-Ibarz J; Schabath MB
    Am J Cardiol; 2019 Aug; 124(4):539-544. PubMed ID: 31208701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib-Associated Atrial Fibrillation.
    Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
    JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
    Chai KL; Rowan G; Seymour JF; Burbury K; Carney D; Tam CS
    Leuk Lymphoma; 2017 Dec; 58(12):2811-2814. PubMed ID: 28504030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
    Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C
    Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.